Author:
Chen Chao,Wang Ying,Huang Haozhe,He Xinhong,Li Wentao
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference24 articles.
1. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119(6):1647–51.
2. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J thor oncol. 2015;10(9):1243–60.
3. Papotti M, Brambilla E, Dingemans AC, Fernandez-Cuesta L, Lantuejoul S, MacMahon H, et al. Carcinoid/Neuroendocrine tumour of the lung. In: WHO Classification of Tumours Editorial Board. Thoracic tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2021. pp. 133–8.
4. Rufini V, Lorusso M, Inzani F, Pasciuto T, Triumbari EKA, Grillo LR, et al. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. Eur J Nucl Med Mol Imaging. 2022;49(12):4182–93.
5. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.